SecBot SecBot

NRSNW

NeuroSense Therapeutics Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001875091 Biotech & Drug Discovery
Warrants of NeuroSense Therapeutics Ltd. · NRSN stock page →
—
Market cap
$14.2K
Nano cap
1 year
−89.2%
from $22.00 · Oct 28
30 days
−53.5%
from $5.10
52-week range
$2.33–24.80
−90% from high · low Oct 26
Avg volume 20D
25.8K
Oct 19 spike 117.6K
Short interest
918
≈0.1% of shares · +2.8%
Days to cover
1.0
at average volume
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 1 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/5
Strongest BULLISH NeuroSense Therapeutics reported a constructive meeting with Health Canada regarding a regulatory pathway…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest +2.8% to 918 shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    59% below its 50-day average. New closing low $2.33 on Oct 26.

Who's buying

13F
Top holderSharesValue
Clear Street Group Inc.63,085$4.0K
UBS Group AG1,163$73.00

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 14, 2026
Trading halt
Halt Resumed: NRSNW — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-11T23:50:00.000Z | Resumed 2026-09-14T13:05:00.000Z
Sep 11, 2026
Trading halt
Trading Halt: NRSNW — T1 (News Pending)
NeuroSense Thera Ltd Wt | Market: NASDAQ | Code: T1 — News Pending
Sep 11, 2026
Trading halt
Trading Halt: NRSNW — T3 (News and Resumption Times)
NeuroSense Thera Ltd Wt | Market: NASDAQ | Code: T3 — News and Resumption Times
Apr 9, 2026
Clinical Trial
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
Phase 2 · TERMINATED

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$2.7M

Short side

FINRA· Oct 15, 2026
918
shares short
+2.8%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Trading halts
Sep 11, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 Trading halt
Halt Resumed: NRSNW — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-11T23:50:00.000Z | Resumed 2026-09-14T13:05:00.000Z
Jun 9, 2026 SEC
NeuroSense Therapeutics received a Japanese patent (No. 7857044) for its lead ALS drug candidate PrimeC, extending…
6-K — Impact 4/10
Jun 8, 2026 SEC
NeuroSense Therapeutics reported a constructive meeting with Health Canada regarding a regulatory pathway for its lead…
6-K — Impact 6/10
Apr 28, 2026 SEC
NeuroSense Therapeutics announced a $600,000 insider-led PIPE financing, with CEO, CFO, and an existing significant…
6-K — Impact 5/10

SecBot reports

8 filings · 1 bullish · 1 bearish · 2 mixed · 4 neutral
All NRSNW filing & press-release reports (8)